Simmons Bank Acquires 3,653 Shares of Edwards Lifesciences Co. (NYSE:EW)

Simmons Bank lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 11.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 35,992 shares of the medical research company’s stock after buying an additional 3,653 shares during the period. Simmons Bank’s holdings in Edwards Lifesciences were worth $2,744,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in EW. Martin Capital Advisors LLP grew its stake in shares of Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after buying an additional 128 shares during the period. Legacy Wealth Asset Management LLC boosted its stake in Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after purchasing an additional 134 shares during the last quarter. DMC Group LLC boosted its stake in Edwards Lifesciences by 4.5% during the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock valued at $272,000 after purchasing an additional 154 shares during the last quarter. Granite Harbor Advisors Inc. boosted its stake in Edwards Lifesciences by 4.2% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock valued at $265,000 after purchasing an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC boosted its stake in Edwards Lifesciences by 2.7% during the 4th quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock valued at $449,000 after purchasing an additional 155 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on EW shares. Citigroup lifted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company lifted their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Mizuho lifted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Barclays boosted their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Morgan Stanley boosted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the sale, the director now owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the sale, the director now owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction on Monday, May 6th. The shares were acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 237,749 shares of company stock valued at $20,920,934 in the last 90 days. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.76 during mid-day trading on Tuesday, reaching $85.85. The company had a trading volume of 1,836,259 shares, compared to its average volume of 3,735,495. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a market cap of $51.73 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 3.59 and a beta of 1.10. The company’s 50-day moving average price is $90.05 and its 200-day moving average price is $79.69. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.